Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Gefitinib in NSCLC
NCT02088112Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2014
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
Phase 1, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by MedImmune. Primary endpoint: Safety and Tolerability up to 32 months. Started Mar 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02088112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088112.